Rosuvastatin and Ezetimibe Effects on Restless Legs Syndrome
Rosuvastatin and ezetimibe have not been shown to worsen restless legs syndrome (RLS) in a consistent, generalizable way in the clinical literature. [1] A 2026 prospective/omics study in Parkinson’s disease reported genetic and observational signals linking HMGCR inhibition (a proxy for statin effect) with RLS phenotypes, which does not establish causality for non-Parkinson’s RLS. [2]
Evidence for Statins and RLS
A 2025 review of medication effects on sleep reported that statins appear to have minimal impact on sleep, with only rare case reports of insomnia or nightmares. [1] No PubMed-indexed evidence directly demonstrating worsening of RLS with rosuvastatin specifically, or with rosuvastatin plus ezetimibe, was identified in the available search results. A 2026 study in Parkinson’s disease used genetic analyses and longitudinal cohort data and reported detrimental effects of HMGCR inhibition on restless legs syndrome in the Parkinson’s disease context. [2]
Evidence for Ezetimibe and RLS
No PubMed-indexed evidence directly linking ezetimibe to RLS worsening was identified in the available search results.
Drug-Drug Combination Considerations
No evidence was identified that the combination of rosuvastatin and ezetimibe specifically worsens RLS beyond any potential class-related effects. [1]
Initiation Thresholds or Indications for RLS Susceptibility
Medication adjustment for suspected RLS worsening is typically guided by clinical temporal association with symptom onset or aggravation after initiation or dose escalation of a medication. No RLS-specific blood-pressure or laboratory threshold is used to decide whether to stop rosuvastatin or ezetimibe.
Common Pitfalls to Avoid
Attributing RLS deterioration to lipid-lowering therapy alone without assessment of common RLS drivers is a frequent error in clinical practice because iron deficiency and renal disease are major contributors. Relying on sleep-medicine reviews focused on insomnia or nightmares rather than RLS-specific outcomes can miss rare or phenotype-specific signals. [1]
Practical Clinical Approach
If worsening RLS symptoms temporally relate to rosuvastatin or ezetimibe exposure, medication change can be considered based on risk–benefit for cardiovascular indication while alternative RLS contributors are evaluated. Continuation is reasonable when RLS symptoms are not temporally linked to statin/ezetimibe initiation and when the cardiovascular benefit is high. [1]
Source-Focused Bottom Consideration for This Case
For a patient taking both rosuvastatin and ezetimibe, the available evidence supports a likelihood of minimal RLS worsening from statin therapy overall, with uncertainty due to lack of RLS-specific direct evidence for rosuvastatin and no direct combination evidence. [1] A Parkinson’s disease–focused signal exists for HMGCR inhibition and RLS, but extrapolation to non-Parkinson’s RLS requires clinical correlation rather than assumption. [2]